The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Open accessAbstract
Purpose: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer. Patients and Methods: DNA was extracted from tumor blocks of patients from E2100. Three hundred sixty-three samples were available to evaluate associations between genotype and outcome. Genotyping was performed for selected polymorphisms in VEGF and VEGF receptor 2. Testing for associations between each polymorphism and efficacy and toxicity was performed. Results: The VEGF-2578 AA genotype was associated with a superior median overall survival (OS) in the combination arm when compared with the alternate genotypes combined (hazard ratio = 0.58; 95% CI, 0.36 to 0.93; P = .023). The VEGF-1154 A allele also demonstrated a superior median OS with an additive effect of each active allele in the combination arm but not the control arm (hazard ratio = 0.62; 95% CI, 0.46 to 0.83; P = .001). Two additional genotypes, VEGF-634 CC and VEGF-1498 TT, were associated with significantly less grade 3 or 4 hypertension in the combination arm when compared with the alternate genotypes combined (P = .005 and P = .022, respectively). Conclusion: Our data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Role of vascular endothelial growth factor in regulation of physiological angiogenesis
Ferrara, N. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1358 · Cited by 1,085
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Self-citationGoetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Self-citationHurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Awata, T., Inoue, K., Kurihara, S., Ohkubo, T., Watanabe, M., Inukai, K., Inoue, I., & Katayama, S. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1635 · Cited by 567
Goodman, V. L., Rock, E. P., Dagher, R., Ramchandani, R. P., Abraham, S., Gobburu, J. V. S., Booth, B. P., Verbois, S. L., Morse, D. E., Liang, C. Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2328 · Cited by 501
Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A. S., Kabbinavar, F., Holden, S. N., Novotny, W. F., Frantz, G. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5388 · Cited by 387
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter.
Stevens, A., Soden, J., Brenchley, P. E., Ralph, S., & Ray, D. W. (2003) · PubMed · Cited by 367
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Influence of cytokine gene polymorphisms on the development of prostate cancer.
McCarron, S. L., Edwards, S. M., Evans, P. R., Gibbs, R., Dearnaley, D. P., Dowe, A., Southgate, C., Easton, D. F., Eeles, R. A., & Howell, W. M. (2002) · PubMed · Cited by 336
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Krippl, P., Langsenlehner, U., Renner, W., Yazdani‐Biuki, B., Wolf, G., Wascher, T. C., Paulweber, B., Haas, J., & Samonigg, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11238 · Cited by 316
Jin, Q., Hemminki, K., Enquist, K., Lenner, P., Grzybowska, E., Klaes, R., Henriksson, R., Chen, B., Pamula, J., Pekala, W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1803 · Cited by 239
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Yang, B., Cross, D. F., Ollerenshaw, M., Millward, B. A., & Demaine, A. G. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00181-2 · Cited by 156
García‐Closas, M., Malats, N., Real, F. X., Yeager, M., Welch, R. A., Silverman, D. T., Kogevinas, M., Dosemeci, M., Figueroa, J. D., Chatterjee, N., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030029 · Cited by 142
Monk, B. J., Han, E. S., Josephs-Cowan, C. A., Pugmire, G., & Burger, R. A. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.006 · Cited by 140
Zon, R. T., Miller, K. D., Wang, M. J., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T., & Davidson, N. E. (2006) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(06)80030-3 · Cited by 134
Self-citationAssociation of polymorphisms of angiogenesis genes with breast cancer
Schneider, B. P., Radovich, M., Sledge, G. W., Robarge, J., Li, L., Storniolo, A. M., Lemler, S. M., Nguyen, A., Hancock, B. A., Stout, M. B., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9755-9 · Cited by 132
Self-citationAssociation of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy.
Balasubbu, S., Rajendran, A., Ramasamy, K., Mahalakshmi, R., Karthikprakash, S., Namperumalsamy, P., & Sundaresan, P. (2006) · PubMed · Cited by 132
Drug Insight: VEGF as a therapeutic target for breast cancer
Schneider, B. P., & Sledge, G. W. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0740 · Cited by 114
Self-citationVEGF polymorphisms and severity of atherosclerosis
Howell, W. M., Ali, S., Rose-Zerilli, M. J., & Ye, S. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.025734 · Cited by 113
Al‐Kateb, H., Mirea, L., Xie, X., Sun, L., Liu, X., Chen, H., Bull, S. B., Boright, A. P., & Paterson, A. D. (2007) · Diabetes · doi:10.2337/db07-0376 · Cited by 110
Tzanakis, Ν., Gazouli, M., Rallis, G., Γιαννόπουλος, Γ., Papaconstantinou, I. G., Theodoropoulos, G. E., Pikoulis, E. A., Tsigris, C., Karakitsos, P., Peros, G., et al. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20619 · Cited by 108
Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome
Sfar, S., Hassen, E., Saad, H., Mosbah, F., & Chouchane, L. (2006) · Cytokine · doi:10.1016/j.cyto.2006.07.003 · Cited by 101
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., Skaar, T. C., Nguyen, A., Desta, Z., Storniolo, A. M., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.14 · Cited by 93
Self-citationRole of genetic polymorphisms in tumour angiogenesis
Balasubramanian, S. P., Brown, N. J., & Reed, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600625 · Cited by 92
Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia
Banyasz, I., Szabó, S. S., Bokodi, G., Vannay, Á., Vásárhelyi, B., Szabo, A. J., Tulassay, T., & Rigó, J. (2006) · Molecular Human Reproduction · doi:10.1093/molehr/gal024 · Cited by 89
Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss
Papazoglou, D., Galazios, G. C., Papatheodorou, K., Liberis, V. A., Παπάνας, Ν., Maltezos, E. S., & Maroulis, G. B. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.12.017 · Cited by 77
Kim, J. G., Sohn, S. K., Chae, Y. S., Cho, Y. Y., Bae, H.-I., Yan, G., Park, J. Y., Lee, M., Chung, H. Y., & Yu, W. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm085 · Cited by 77
Shim, J., Jun, J. K., Jung, B., Kim, S. H., Won, H., Lee, P. R., & Kim, A. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.06.045 · Cited by 68
Biomarker for hypertension-preeclampsia: are we close yet?
Sibai, B. M. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.04.021 · Cited by 63
VEGF –460 genotype plays an important role in progression to chronic kidney disease stage 5
Summers, A., Coupes, B. M., Brennan, M. F., Ralph, S., Short, C. D., & Brenchley, P. E. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi029 · Cited by 51
Doi, K., Noiri, E., Nakao, A., Fujita, T., Kobayashi, S., & Tokunaga, K. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010094 · Cited by 47
Bányász, I., Bokodi, G., Vannay, Á., Szebeni, B., Treszl, A., Vásárhelyi, B., Tulassay, T., & Szabó, A. (2006) · Current Eye Research · doi:10.1080/02713680600801123 · Cited by 42
Errera, F. I. V., Canani, L. H. S., Silva, M. E. R., Yeh, E., Takahashi, W. Y., dos Santos, K. G., Souto, K. E. P., Tschiedel, B., Roisenberg, I., Gross, J. L., et al. (2007) · Diabetes Care · doi:10.2337/dc06-1399 · Cited by 42
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Adverse effects of anticancer agents that target the VEGF pathway
Chen, H. X., & Cleck, J. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.94 · Cited by 560
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Metadata
- Authors
- Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., Dickler, M., Perez, E. A., Cobleigh, M., Shenkier, T., Edgerton, S., & Miller, K. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-01
- Volume
- 26
- Issue
- 28
- Pages
- 4672-4678
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131705241
- Cited by
- 604
- References
- 44
- FWCI
- 27.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.